Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Xavier Milara (Valencia, Spain), Javier Milara, Adela Serrano, Julio Cortijo, Srikant Viswanadha, Swaroop Vakkalanka. LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients. Eur Respir J 2015; 46: Suppl. 59, 286

Member's Comments

No comment yet.

Related content which might interest you: PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 LATE-BREAKING ABSTRACT: DS102: A bioactive lipid for the treatment of chronic pulmonary disorders Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016 LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 LATE-BREAKING ABSTRACT: TSLP as a potent activator of Th2 response in obstructive lung diseases Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects Source: Eur Respir J 2010; 35: 564-570 Year: 2010 LATE-BREAKING ABSTRACT: Andrographolide helps steroid-resistant cigarette smoke-induced lung injury model to regain steroid sensitivity Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016 LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 LATE-BREAKING ABSTRACT: alpha-1 antitrypsin activates protein phosphatase 2A (PP2A) to counter lung inflammatory responses Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015